[Hematology in the time of COVID-19]

Area of Science:

• Hematology
• Infectious Diseases
• Oncology

Background:

• The COVID-19 pandemic presents unique challenges for hematology practices.
• Managing hematologic conditions during a pandemic requires careful consideration of treatment protocols and patient risk.
• Hematologic patients, particularly those with sickle cell anemia, may be at increased risk for severe COVID-19 outcomes.

Purpose of the Study:

• To provide guidance on managing hematologic conditions during the COVID-19 pandemic.
• To outline necessary adjustments in chemotherapy, stem cell transplantation, and treatment for various hematologic malignancies.
• To address specific considerations for patients with myeloid neoplasia, sickle cell anemia, and those experiencing thrombocytopenia or a procoagulant state.

Main Methods:

• Review of current hematologic treatment guidelines in the context of the COVID-19 pandemic.
• Analysis of the impact of COVID-19 on patients with specific hematologic conditions.
• Assessment of the risks associated with blood product transfusion and SARS-CoV-2 transmission.

Main Results:

• High-grade lymphomas, acute leukemias, multiple myeloma, and most stem cell transplantations should proceed as usual.
• Low-grade lymphomas and maintenance therapies may be postponed if not strictly indicated.
• Sickle cell anemia patients require vigilant management due to susceptibility to severe COVID-19; thrombocytopenia and procoagulant states necessitate individualized therapy.

Conclusions:

• Hematologic practices must adapt to the COVID-19 pandemic, balancing essential treatments with risk mitigation.
• Specific patient populations, such as those with sickle cell anemia or certain hematologic malignancies, require tailored management strategies.
• Current evidence suggests no significant risk of SARS-CoV-2 transmission via blood product transfusion.